

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number
WO 01/21198 A1

(51) International Patent Classification⁷: A61K 38/29,
A61P 35/04, 19/08 // (A61K 38/29, 31:59) (A61K 38/29,
30:06) (A61K 38/29, 31:59, 30:06)

(21) International Application Number: PCT/US00/24746

(22) International Filing Date:
11 September 2000 (11.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/155,455 20 September 1999 (20.09.1999) US

(71) Applicant (for all designated States except US): ELI
LILLY AND COMPANY [US/US]; Lilly Corporate
Center, Indianapolis, IN 46285 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): HOCK, Janet, M.
[US/US]; 7702 Candlewood Lane, Indianapolis, IN 46250
(US).

(81) Designated States (national): AE, AG, AL, AM, AT, AT
(utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA,

CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility
model), DK, DK (utility model), DM, DZ, EE, EE (utility
model), ES, FI, FI (utility model), GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility
model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,
MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT,
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR REDUCING THE RISK OF CANCER

(57) Abstract: Methods for decreasing the risk of cancer by administering a parathyroid hormone are disclosed. More particularly, the disclosed methods are for decreasing the risk of cancer in a person at risk of developing cancer, including persons at relatively low risk of osteoporosis, or at high risk of or suffering from osteoporosis. The methods are particularly effective for decreasing risks of breast or skin carcinoma.

WO 01/21198 A1

METHOD FOR REDUCING THE RISK OF CANCER

TECHNICAL FIELD

This invention relates to a method for decreasing the risk of developing
5 cancer by administering a parathyroid hormone. More particularly, the invention
relates to a method for decreasing the risk of cancer in a person at risk of developing
cancer, including persons at relatively low risk of osteoporosis, or at high risk of or
suffering from osteoporosis. The invention relates more particularly to a method for
decreasing risks of breast or skin carcinoma.

10

BACKGROUND OF THE INVENTION

Cancers are cellular tumors, or masses, that, when not treated, grow.
Untreated cancers typically invade other tissues, spread, and are fatal.

Many human cancers are thought to involve genetic mutations. These
15 genetic mutations result in, for example, the conversion of protooncogenes to
oncogenes and/or dysfunction of tumor suppressor genes. Some of these mutations
appear to be inherited or to cluster in families. Thus, a person with a family member
that has had cancer may be at increased risk of cancer. Other genetic mutations
occur spontaneously by, for example, exposure to a carcinogenic agent. Subjects
20 carrying particular genetic mutations of particular genes, such as the *p53*, *BRCA1*
and *RBI* genes, are at increased risk of developing certain types of cancer, including
breast cancer and retinoblastoma.

Nonetheless, about 95% of breast cancer cases are thought to be sporadic,
having a cause other than an inherited genetic mutation. Additional risk factors for
25 cancers such as breast cancer include increasing age, exposure to a chemical
carcinogen, to an immunosuppressive drug, or to a viral infection, and physical
factors such as radiation. With these many risk factors, some estimate that 10% of
the female human population will develop breast cancer during their lifetime. More
particularly, for instance, populations considered to be at relatively high risk of
30 breast cancer can be defined using the Gail model. Gail MH, Brinton LA, Byar DP
et al (1989) Projecting individualized probabilities of developing breast cancer for
white females who are being examined annually. J Natl Cancer Inst 81:1879-1886.

Hormones such as estrogen have been associated with the etiology of particular cancers such as breast and endometrial cancer. For instance, see Cauley JA Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR (1999). Elevated serum estradiol and testosterone concentrations are associated with a high risk of breast cancer. Study of Osteoporotic Fractures Research Group. Annals of Inter Med. 130:270-277. Paradoxically, a significant portion of the population at risk for breast cancer is being treated with estrogen. Although subjects with osteoporosis and low bone mass are less likely to exhibit breast cancer than other women, avoiding estrogen therapy can still be desirable. Accordingly, forms of therapy, other than estrogen replacement therapy, for the treatment of osteoporosis and/or the reduction of risk of bone trauma are needed, and methods for reducing the risk of breast cancer that also treat or reduce the risk of osteoporosis would be beneficial.

Therefore, an evaluation of the ability of therapeutic compositions useful for treating osteoporosis to reduce the risk of breast cancer is a matter of pressing need. Demonstrations of ability of a composition to reduce the risk of breast cancer in human subjects are most convincing in clinical trials using such subjects, but this ability may also be usefully predicted using recognized animal models. See, for instance, Anzano MA, Peer CW, Smith JM et al (1996) Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 88:123-125.

Parathyroid hormone (PTH) is a therapeutic agent which has beneficial bone forming properties. Parathyroid hormone (PTH) is a secreted, 84 amino acid product of the mammalian parathyroid gland that controls serum calcium levels through its action on various tissues, including bone. The N-terminal 34 amino acids of bovine and human PTH (PTH(1-34)) is deemed biologically equivalent to the full length hormone. Other amino terminal fragments of PTH (including 1-31 and 1-38 for example), or PTHrP (PTH-related peptide/protein) or analogues of either or both, that activate the PTH/PTHrP receptor (PTH1 receptor) have shown similar biologic effects on bone mass, although the magnitude of such effects may vary.

The perceived roles of PTH and the PTH-related protein (PTHrP) in breast cancer remain unclear and have changed over time. PTH was once implicated as a

possible agent in promoting the skeletal metastases associated with breast cancer. Subsequently, the PTHrP has been determined to be the causative agent of humoral hypercalcemia of malignancy, and a key factor in promoting skeletal metastases of solid tumors. The scientific literature reports that those relatively rare patients with
5 both hyperparathyroidism, which increases PTH levels, and breast cancer exhibit significantly longer survival than breast cancer patients without hyperparathyroidism. Still, many studies focus on the role of PTHrP in breast cancer.

For example, increased serum PTHrP has been used as a diagnostic to search
10 for an occult tumor. One study found that an increase in serum PTHrP had a 69% predictive value of death within 100 days. However, another study failed to find predictive value in PTHrP levels. Another study supports the assertion that, as a diagnostic, increased PTHrP does not predict additional breast cancer cases beyond those already identified by the current markers.

15 Other workers maintain that PTHrP levels may be predictive of the progression of breast cancer. For example, one study indicates that increased PTHrP is found in hypercalcemia of malignancy and when skeletal metastases are present. Other reports indicate that although there is a significant correlation between the expression of PTHrP and proliferation markers, this correlation does not necessarily
20 exist between PTHrP and hypercalcemia. A retrospective study of breast cancer cells showed various promoter-initiated transcripts and PTHrP 1- 139 mRNA in cases that progressed to metastases, especially bone metastases. Certain of the promoter-initiated transcripts were associated with the absence of estrogen receptors on the breast tumors.

25 However, the sample size of these studies was small and PTHrP may also be expressed in 30% of normal breast tissue. Further, there is also significant heterogeneity in the responsiveness of cell clones isolated from breast cancer. This heterogeneity was evidenced through expression of the PTH1 receptor, the mitogenic response, and the tumor cell's ability to invade Matrigel substrate when
30 exposed to PTHrP fragments *in vitro*. Therefore, some workers conclude that PTHrP levels may not be predictive of even metastasis.

Studies of the receptors for PTH and PTHrP have not clarified the roles of

these proteins in breast cancer. Immunocytochemical and *in situ* histohybridization studies show both PTHrP and PTH1 receptor (PTH1R) can be localized to malignant breast lesions. Between 50% and 70% of human breast cancers express PTHrP, and 50-96% express the PTH1R. Isolated breast cancer cells lines show PTHrP and/or
5 the PTH1 receptor in both estrogen-positive (ER+) and estrogen-negative (ER-) cells. The ER+ breast cancer cell line, MCF-7, which produces PTHrP and expresses PTH1R proliferates in response to PTHrP in vitro. Although PTH and PTHrP bind competitively to the PTH1 receptor, there is no evidence to show that one ligand would be favored over the other.

10 Studies in humans with various forms of PTH have demonstrated an anabolic effect on bone, and have prompted significant interest in its use for the treatment of osteoporosis and related bone disorders. The significant anabolic effects of PTH on bone, including stimulation of bone formation which results in a net gain in bone mass and/or strength, have been demonstrated in many animal models and in
15 humans.

It is commonly believed that PTH administration in humans and in relevant animal models has a negative effect on cortical bone. In fact, naturally occurring increases in endogenous PTH, which occur in the disorder hyperparathyroidism, result in thinning of cortical bone accompanied by an increase in connectivity and
20 mass of trabecular bone. Past studies suggest that when Haversian cortical bone (found in humans and higher mammals) remodels under the influence of PTH, there will be a re-distribution of bone such that cortical bone mass and strength decrease, while trabecular bone increases in mass and strength. For example, in published clinical studies of administering PTH, cortical bone mass decreased after treatment
25 with exogenous PTH and these findings have raised concern that treatment with PTH will lead to reduced cortical bone mass and strength. One concern raised by such studies is that there would be a loss of total skeletal bone mass due to the loss of cortical bone. This is of high clinical relevance as, in osteoporosis, the greater loss of trabecular bone compared to loss of cortical bone, means that mechanical
30 loading is predominantly borne by the remaining cortical bone. Continued loss of cortical bone would increase the fracture risk. Therefore, it is important that a therapeutic agent for osteoporosis maintain or increase residual cortical bone.

The effects of PTH on cortical bone have been investigated in nonhuman animals with Haversian remodeling, such as dogs, ferrets, sheep and monkeys, but sample sizes are typically too small for reliable statistical analysis. The impact of the changes induced by PTH treatment on mechanical properties of cortical bone in
5 such animals remains unknown. Published studies of rodents have shown increased cortical bone mass during administration of PTH but a loss of this benefit after withdrawal of PTH. However, rodent cortical bone has a distinctly different structure from Haversian cortical bone, and remodels by surface appositional formation and resorption, rather than by intracortical remodeling of osteons.
10 Furthermore, technological limitations in biomechanical testing on the relatively short bones of rodents give rise to artifacts of measurement when an agent, such as a PTH, alters bone geometry to thicken the bone. Such artifacts make extrapolation of rat cortical bone responses to those of humans or other animals with osteonal remodeling unreliable. Therefore, the existing data for animals, like humans,
15 undergoing Haversian remodeling indicates that PTH may have an adverse impact on cortical bone, causing net loss of bone mass through depletion of cortical bone.

As a consequence, it has been a popular belief regarding the action of PTH that patients may not achieve sufficient benefit from administration of PTH to justify its use. In fact, it is commonly believed that patients require additional drug therapy
20 to treat or prevent conditions or disorders that accompany osteoporosis or bone trauma. For example it is believed that osteoporosis patients require concurrent or subsequent treatment with an antiresorptive to minimize loss of bone induced by PTH. It was also believed that patients would require additional medications to reduce the risk of or to treat disorders such as cancer, diabetes, cerebrovascular
25 disorder, and other disorders that affect subjects that might otherwise benefit from administration of PTH. In fact, this model requiring additional therapeutic agents for additional indications has been the basis for several clinical studies in women. For example, three clinical studies have used PTH in post-menopausal women undergoing concurrent therapy with calcitonin or estrogen, or in premenopausal
30 women taking GnRH agonist, Synarel, for endometriosis. The opposing effects of estrogen and PTH on cortical bone turnover make it particularly difficult to observe effects of just PTH during combination therapy with these two agents.

SUMMARY OF THE INVENTION

The present invention includes methods for decreasing the risk of cancer in a subject by administering a parathyroid hormone. The method preferably decreases the risk of skin carcinoma and breast carcinoma, preferably breast carcinoma. A preferred subject for the method of the invention is a human subject at risk of developing a carcinoma, particularly breast carcinoma, skin carcinoma, bladder carcinoma, gastric carcinoma, or a combination thereof. The subject at risk of developing cancer may have a relatively low risk of osteoporosis or a high risk of or be suffering from osteoporosis. In one preferred embodiment, the subject is a woman identified as having a relatively high risk of breast cancer. The high risk of breast cancer may be based on known risk factors including age at menarche, age at first live birth, number of previous biopsies, and number of first-degree relatives with breast cancer. The high risk of breast cancer also may be based on a relatively high level of bioavailable serum estradiol or of free testosterone. In another preferred embodiment, the subject is a woman identified as having a high risk of or as suffering from osteoporosis, preferably a postmenopausal woman. A preferred subject in this embodiment is not concurrently taking hormone replacement therapy (HRT), estrogen or equivalent therapy, or antiresorptive therapy. In one embodiment, the patient also receives supplements of calcium and/or vitamin D.

A parathyroid hormone, such as the N-terminal amino acids 1-34 of recombinant human parathyroid hormone, can be administered either cyclically or intermittently. Preferably, this hormone is administered in a daily dose in the range of at least about 15 μ g to about 40 μ g, for at least about 12 months. The hormone is administered with or without concurrent administration of an antiresorptive agent, including vitamin D or calcium. In another embodiment, the invention provides an article of manufacture comprising packaging material and a pharmaceutical composition contained within that packaging material, where the composition comprises a parathyroid hormone consisting of amino acid sequence 1-34 of human parathyroid and the packaging material comprising printed matter which indicates that the composition is effective for reducing the risk of cancer in human subject in need thereof when administered according to the present invention.

DETAILED DESCRIPTION

The invention relates to a method for reducing the risk of cancer in a subject. In one embodiment the invention relates to a method for reducing the risk of breast carcinoma and/or skin carcinoma, preferably breast carcinoma. In another
5 embodiment, the invention relates to a method for reducing the risk of cancer in a subject at risk for suffering from osteoporosis and/or bone fracture, by administering a parathyroid hormone.

As used herein, reducing risk or incidence includes decreasing the probability or incidence of an indication, disease, or disorder for a subject compared to a
10 relevant, e.g. untreated, control population, or in the same subject prior to treatment according to the invention. Reduced risk or incidence can include delaying or preventing the onset of an indication, disease, or disorder. Risk or incidence can also be reduced if the severity of an indication, disease, or disorder is reduced to a level such that it is not of clinical relevance. That is, the indication, disease, or
15 disorder may be present but at a level that does not endanger the life, activities, and/or well being of the subject. For example, a small tumor may regress and disappear, or remain static. Preferably tumor formation does not occur. In some circumstances the occurrence of the disorder is reduced to the extent that the subject does not present any signs of the indication, disease, or disorder during and/or after
20 the treatment period.

Additional aspects of methods employing administration of a parathyroid hormone are described in U.S. Patent Application No. 60/099,746 and PCT Patent Application No. PCT/US99/18961, published as WO 00/10596 on 2 March 2000, which claims priority to the above U.S. application, the disclosures of which are
25 incorporated herein by reference.

Cancer

The method of the invention benefits a subject at risk of developing cancer by decreasing the probability that the subject gets cancer. As used herein, the term
30 "cancer" includes any cellular tumor, or mass, that, when not treated, grows. As used herein, the term "carcinoma" includes any cancer that arises from epithelial tissue. The method of the invention can reduce the risk of a variety of cancers of

carcinomas, such as skin carcinoma, breast carcinoma, bladder carcinoma, gastric carcinoma, and the like.

If left untreated, a cancer typically invades other tissues, spreads, and eventually results in death. By reducing the incidence of cancer, the present invention prevents or reduces the likelihood of this invasion, spread, and death. Cancers can arise from a variety of causes, and the present invention can be effective in reducing risk of cancers due to, for example, increased age, family history of cancer, exposure to chemical carcinogens, an immunosuppressive drug, viral infection, or physical factors such as radiation. Many cancers are thought to involve genetic mutations that result in, for example, the conversion of protooncogenes to oncogenes and/or dysfunction of tumor suppressor genes. The method of the present invention can, for example, reduce the risk of breast cancer in subjects carrying mutations associated with breast cancer and retinoblastoma, such as mutations of the *BRCA1* gene or the *RBI* gene.

Certain cancers, such as breast, prostate and lung cancer, can spread to bone. The present method can also ameliorate the damage from metastasis to bone, particularly when the spread to bone has caused a significant defect in the bone. For example, reducing the risk of cancer reduces the incidence of cancer that can spread to a bone. Administration of a parathyroid hormone also has beneficial effects on bone that can reduce the spread of a cancer in a bone and also reduce the damage that occurs to the bone when the cancer is established and grows. Further, administration of a parathyroid hormone also has beneficial effects on bone that can reduce the damage to occurs to the bone when the cancer is being treated, is in regression, or is otherwise being reduced in size. When the cancer has been stopped, the defect in bone remains and the bone remains at risk of fracture or other trauma. The present invention can aid maintenance and rebuilding of the bone in a cancer patient undergoing or at risk of metastasis or other growth of a tumor in bone. That is, the present method can reduce the risk of fracture in such bone, can increase toughness and stiffness of the bone, can increase the subject's freedom of movement, and the like.

Breast Cancer

The method of the invention can benefit a subject at risk of developing breast cancer by reducing the probability that they get cancer. The method of the invention can reduce the risk of various types of breast cancer, for example, those cancers due
5 to or correlated with a genetic mutation in a tumor suppressor gene, e.g. *p53*, *BRCA1*, and the like. Risk of breast cancer of sporadic origin, or due to, for example, increased age, family history of cancer, exposure to chemical carcinogens, an immunosuppressive drug, viral infection, or physical factors such as radiation can also be reduced by the method of the invention. The present method can reduce the
10 risk of estrogen dependent and estrogen independent breast cancers. Preferably, the method of the invention is employed to reduce breast cancer in a woman.

More particularly, populations considered to be in need of treatment according to the present invention to reduce high risk of breast cancer can be defined using the Gail model. Gail MH, Brinton LA, Byar DP et al (1989) Projecting
15 individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879-1886. This paper discloses a method to estimate the chance that a woman with given age and risk factors will develop breast cancer over a specified interval. The risk factors used were age at menarche, age at first live birth, number of previous biopsies, and number of first-
20 degree relatives with breast cancer. A model of relative risks for various combinations of these factors was developed from case-control data from the Breast Cancer Detection Demonstration Project (BCDDP). The model allowed for the fact that relative risks associated with previous breast biopsies were smaller for women aged 50 or more than for younger women. Thus, the proportional hazards models
25 for those under age 50 and for those of age 50 or more. The baseline age-specific hazard rate, which is the rate for a patient without identified risk factors, is computed as the product of the observed age-specific composite hazard rate times the quantity 1 minus the attributable risk. The authors calculated individualized breast cancer probabilities from information on relative risks and the baseline hazard rate. The
30 authors presented tables for estimating individualized absolute risks of developing breast cancer. They also pointed out the methods disclosed in this article may be used to help design prevention trials in high-risk populations, because an important

determinant of the required sample size is the absolute risk of developing breast cancer in such a population.

Estrogen is thought to play a role in the etiology of certain breast cancers. For instance, see Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR (1999). In particular, elevated serum estradiol and testosterone concentrations are associated with a high risk of breast cancer. Study of Osteoporotic Fractures Research Group. Annals of Inter Med. 130:270-277. This article discloses that measurement of sex hormone levels may identify women at high risk for breast cancer who should consider preventive therapies. In a prospective case-cohort study of 97 women with confirmed incident breast cancer and 244 randomly selected controls; sex-steroid hormone concentrations were assayed by using serum that was collected at baseline and stored at -190 degrees C. Risk factors for breast cancer were ascertained by questionnaire. Incident cases of breast cancer were confirmed by review of medical records during an average period of 3.2 years. The authors found that the relative risk for breast cancer in women with the highest concentration of bioavailable estradiol (≥ 6.83 pmol/L or 1.9 pg/mL) was 3.6 (95% CI, 1.3 to 10.0) compared with women with the lowest concentration. The risk for breast cancer in women with the highest concentration of free testosterone compared with those with the lowest concentration was 3.3 (CI, 1.1 to 10.3). The estimated incidence of breast cancer per 1000 person-years was 0.4 (CI, 0.0 to 1.3) in women with the lowest levels of bioavailable estradiol and free testosterone compared with 6.5 (CI, 2.7 to 10.3) in women with the highest concentrations of these hormones. Traditional risk factors for breast cancer were similar in case-patients and controls. Adjustments for these risk factors had little effect on the results. The authors therefore concluded that estradiol and testosterone levels may play important roles in the development of breast cancer in older women. Further, a single measurement of bioavailable estradiol and free testosterone may be used to estimate a woman's risk for breast cancer. The authors also noted that women identified as being at high risk for breast cancer as determined by these hormone levels may benefit from antiestrogen treatment for primary prevention. According to the present invention, women identified as being at high risk for breast cancer as determined by these same

hormone levels also would benefit from treatment with parathyroid hormone as taught herein.

Subjects who would benefit from reduction of risk for developing cancer by the present invention may or may not also be at relatively high risk of or suffering from osteoporosis or osteopenia. For instance, while elevated serum estradiol concentrations are associated with a high risk of breast cancer, low levels of serum estradiol concentrations are associated with low bone density and increased risk of fractures among elderly women with osteoporosis. See Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Cummings SR (1998) Associations between low levels of serum estradiol, bone density and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab 83:2239-2243. More particularly, this report discloses a study to evaluate the skeletal effects of endogenous serum estradiol. The authors measured bone mineral density (BMD) at the calcaneus and radius (single photon absorptiometry) and at the hip and spine (dual x-ray absorptiometry) in 274 women aged 65 yr or more who participated in the Study of Osteoporotic Fractures. Lateral radiographs of the thoracic and lumbar spine were also taken, and serum was assayed for estradiol. Those who had estradiol levels from 10-25 pg/mL had 4.9%, 9.6%, 7.3%, and 6.8% greater BMD at total hip, calcaneus, proximal radius, and spine than those with levels below 5 pg/mL. After multiple adjustments, BMD differences remained statistically significant and corresponded to about 0.4 SD. Vertebral deformities were less prevalent among women whose estradiol level exceeded 5 pg/mL; the multiple adjusted odds ratio was 0.4 (95% confidence interval, 0.2-0.8). The authors concluded that physiologically low estradiol has a salutary effect on the skeleton in elderly women, possibly by reducing skeletal remodeling. Accordingly, women identified as being at highest risk for breast cancer as determined by serum estradiol levels, as discussed above, would be expected to be at lowest risk for developing osteoporosis.

The present invention also reduces the need to administer estrogen to a population at risk of estrogen-dependent breast cancer. The method of the present invention provides a method that does not require estrogen replacement therapy, that provides reduction in the risk of breast cancer, and that also reduces the effects or

progression of osteoporosis and/or the reduces risks of osteoporosis and bone trauma.

Thus, breast cancer can spread to bone. The present method can also treat metastases to bone, particularly when the spread to bone has caused a significant defect in the bone. When the cancer is treated, the defect in bone remains and the bone remains at risk of fracture or other trauma. The present invention can aid rebuilding of the bone. That is, the present method can reduce the risk of fracture in such bone, can increase toughness and stiffness of the bone, can increase the subject's freedom of movement, and the like.

10

Skin Cancer

The method of the invention can benefit a subject at risk of developing skin cancer by reducing the probability that they get cancer. The method of the invention can reduce the risk of skin cancer due to a genetic mutations and/or exposure to radiation, such as sunlight in the form of ultraviolet radiation. The present method also can reduce risk of skin cancer due to, for example, increased age, family history of cancer, exposure to chemical carcinogens, an immunosuppressive drug, viral infection, and the like.

Bone Trauma

The method of the invention is of benefit to a subject that may suffer or have suffered trauma to one or more bones. The method can benefit mammalian subjects, such as humans, horses, dogs, and cats, in particular, humans. Bone trauma can be a problem for racing horses and dogs, and also for household pets. A human can suffer any of a variety of bone traumas due, for example, to accident, medical intervention, disease, or disorder. Metastasis of cancer to the bone can result in a bone defect that puts the bone at risk of trauma. In the young, bone trauma is likely due to fracture, medical intervention to repair a fracture, genetic disorders that increase susceptibility to bone fracture or bone lytic lesions, or the repair of joints or connective tissue damaged, for example, through athletics. Other types of bone trauma, such as those from osteoporosis, degenerative bone disease (such as arthritis or osteoarthritis), hip replacement, or secondary conditions associated with therapy

25
30

for other systemic conditions (e.g., glucocorticoid osteoporosis, burns or organ transplantation) are found most often in older people.

Bone trauma can be a problem for subjects at risk of cancer. For example, many subjects with the disorders described above also are at risk of, have some risk factors for, or actually have cancer, such as skin cancer or breast cancer. In particular, women with or at risk of osteoporosis can also be at risk of or have breast carcinoma. Further, a subject's cancer may have metastasized to the bone. The method of the invention can benefit these types of subjects.

Preferred subjects include a human, preferably a woman, at risk for or suffering from osteoporosis. Risk factors for osteoporosis are known in the art and include hypogonadal conditions in men and women, irrespective of age, conditions, diseases or drugs that induce hypogonadism, nutritional factors associated with osteoporosis (low calcium or vitamin D being the most common), smoking, alcohol, drugs associated with bone loss (such as glucocorticoids, thyroxine, heparin, lithium, anticonvulsants etc.), loss of eyesight or walking styles that predisposes to falls, space travel, immobilization, chronic hospitalization or bed rest, and other systemic diseases that have been linked to increased risk of osteoporosis. Indications of the presence of osteoporosis are known in the art and include radiological evidence of at least one vertebral compression fracture, low bone mass (typically at least 1 standard deviation below mean young normal values), and/or atraumatic fractures.

The method of the invention can benefit subjects suffering from, or at risk of, osteoporosis by, for example, reducing risk of cancer, such as breast cancer. The present invention provides a method, in particular, effective for reducing risk of cancer, such as breast cancer, in a subject with or at risk of progressing to osteoporosis or patients in which spinal osteoporosis may be progressing rapidly. A typical woman at risk for osteoporosis is a postmenopausal woman or a premenopausal, hypogonadal woman. A preferred subject is a postmenopausal woman who is not concurrently taking hormone replacement therapy (HRT), estrogen or equivalent therapy, or antiresorptive therapy. The method of invention can benefit a subject at any stage of osteoporosis, but especially in the early and advanced stages.

Other subjects can also be at risk of or suffer bone trauma and can benefit from the method of the invention. For example, a wide variety of subjects at risk of

one or more of the fractures identified above, can anticipate surgery resulting in bone trauma, or may undergo an orthopedic procedure that manipulates a bone at a skeletal site of abnormally low bone mass or poor bone structure, or deficient in mineral. For example, recovery of function after a surgery such as a joint replacement (e.g. knee or hip) or spine bracing, or other procedures that immobilize a bone or skeleton can improve due to the method of the invention. The method of the invention can also aid recovery from orthopedic procedures that manipulate a bone at a site of abnormally low bone mass or poor bone structure, which procedures include surgical division of bone, including osteotomies, joint replacement where loss of bone structure requires restructuring with acetabulum shelf creation and prevention of prosthesis drift, for example. Other suitable subjects for practice of the present invention include those suffering from hypoparathyroidism or kyphosis, who can undergo trauma related to, or caused by, hypoparathyroidism or progression of kyphosis.

15

Parathyroid Hormone

As active ingredient, the composition or solution may incorporate the full length, 84 amino acid form of parathyroid hormone, particularly the human form, hPTH (1-84), obtained either recombinantly, by peptide synthesis or by extraction from human fluid. See, for example, U.S. Pat. No. 5,208,041, incorporated herein by reference. The amino acid sequence for hPTH (1-84) is reported by Kimura et al. in Biochem. Biophys. Res. Comm., 114(2):493.

20

The composition or solution may also incorporate as active ingredient fragments or variants of fragments of human PTH or of rat, porcine or bovine PTH that have human PTH activity as determined in the ovariectomized rat model of osteoporosis reported by Kimmel et al., Endocrinology, 1993, 32(4):1577.

25

The parathyroid hormone fragments desirably incorporate at least the first 28 N-terminal residues, such as PTH(1-28), PTH(1-31), PTH(1-34), PTH(1-37), PTH(1-38) and PTH(1-41). Alternatives in the form of PTH variants incorporate from 1 to 5 amino acid substitutions that improve PTH stability and half-life, such as the replacement of methionine residues at positions 8 and/or 18 with leucine or other hydrophobic amino acid that improves PTH stability against oxidation and the

30

replacement of amino acids in the 25-27 region with trypsin-insensitive amino acids such as histidine or other amino acid that improves PTH stability against protease. Other suitable forms of PTH include PTHrP, PTHrP(1-34), PTHrP(1-36) and analogs of PTH or PTHrP that activate the PTH1 receptor. These forms of PTH are
5 embraced by the term "parathyroid hormone" as used generically herein. The hormones may be obtained by known recombinant or synthetic methods, such as described in U.S. Pat. Nos. 4,086,196 and 5,556,940, incorporated herein by reference.

The preferred hormone is human PTH(1-34). Stabilized solutions of human
10 PTH(1-34), such as recombinant human PTH(1-34) (rhPTH(1-34)), that can be employed in the present method are described in U.S. Patent Application Serial No. 60/069,075, incorporated herein by reference. Crystalline forms of human PTH(1-34) that can be employed in the present method are described in U.S. Patent Application Serial No. 60/069,875, incorporated herein by reference.

15

Administering Parathyroid Hormone

A parathyroid hormone can typically be administered parenterally, preferably by subcutaneous injection, by methods and in formulations well known in the art. Stabilized formulations of human PTH(1-34) that can advantageously be employed
20 in the present method are described in U.S. Patent Application Serial No. 60/069,075, incorporated herein by reference. This patent application also describes numerous other formulations for storage and administration of parathyroid hormone. A stabilized solution of a parathyroid hormone can include a stabilizing agent, a buffering agent, a preservative, and the like.

25 The stabilizing agent incorporated into the solution or composition includes a polyol which includes a saccharide, preferably a monosaccharide or disaccharide, e.g., glucose, trehalose, raffinose, or sucrose; a sugar alcohol such as, for example, mannitol, sorbitol or inositol, and a polyhydric alcohol such as glycerine or propylene glycol or mixtures thereof. A preferred polyol is mannitol or propylene
30 glycol. The concentration of polyol may range from about 1 to about 20 wt-%, preferably about 3 to 10 wt-% of the total solution.

The buffering agent employed in the solution or composition of the present

invention may be any acid or salt combination which is pharmaceutically acceptable and capable of maintaining the aqueous solution at a pH range of 3 to 7, preferably 3-6. Useful buffering systems are, for example, acetate, tartrate or citrate sources. Preferred buffer systems are acetate or tartrate sources, most preferred is an acetate
5 source. The concentration of buffer may be in the range of about 2 mM to about 500 mM, preferably about 2 mM to 100 mM.

The stabilized solution or composition of the present invention may also include a parenterally acceptable preservative. Such preservatives include, for example, cresols, benzyl alcohol, phenol, benzalkonium chloride, benzethonium
10 chloride, chlorobutanol, phenylethyl alcohol, methyl paraben, propyl paraben, thimerosal and phenylmercuric nitrate and acetate. A preferred preservative is m-cresol or benzyl alcohol; most preferred is m-cresol. The amount of preservative employed may range from about 0.1 to about 2 wt-%, preferably about 0.3 to about 1.0 wt-% of the total solution.

15 Thus, the stabilized PTH solution can contain mannitol, acetate and m-cresol with a predicted shelf-life of over 15 months at 5°C.

The parathyroid hormone compositions can, if desired, be provided in a powder form containing not more than 2% water by weight, that results from the freeze-drying of a sterile, aqueous hormone solution prepared by mixing the selected
20 parathyroid hormone, a buffering agent and a stabilizing agent as above described. Especially useful as a buffering agent when preparing lyophilized powders is a tartrate source. Particularly useful stabilizing agents include glycine, sucrose, trehalose and raffinose.

In addition, parathyroid hormone can be formulated with typical buffers and
25 excipients employed in the art to stabilize and solubilize proteins for parenteral administration. Art recognized pharmaceutical carriers and their formulations are described in Martin, "Remington's Pharmaceutical Sciences," 15th Ed.; Mack Publishing Co., Easton (1975). A parathyroid hormone can also be delivered via the lungs, mouth, nose, by suppository, or by oral formulations.

30 The parathyroid hormone is formulated for administering a dose effective for reducing a subject's risk of cancer, particularly breast cancer. Preferably, a subject receiving parathyroid hormone also receives effective doses of calcium and vitamin

D, which can enhance the effects of the hormone. An effective dose of parathyroid hormone is typically greater than about 5 µg/kg/day although, particularly in humans, it can be as large as about 10 to about 40 µg/day per subject, regardless of body mass, or larger as is effective for reducing a subject's risk of cancer, particularly breast cancer. A subject suffering from hypoparathyroidism can require additional or higher doses of a parathyroid hormone; such a subject also requires replacement therapy with the hormone. Doses required for replacement therapy in hypoparathyroidism are known in the art. In certain instances, relevant effects of PTH can be observed at doses less than about 5 µg/kg/day, or even less than about 1 µg/kg/day.

The hormone can be administered regularly (e.g., once or more each day or week), intermittently (e.g., irregularly during a day or week), or cyclically (e.g., regularly for a period of days or weeks followed by a period without administration). Preferably PTH is administered once daily for 1-7 days per week over a period ranging from 3 months for up to 3 years in osteoporotic patients. Preferably, cyclic administration includes administering a parathyroid hormone for at least 2 remodeling cycles and withdrawing parathyroid hormone for at least 1 remodeling cycle. Another preferred regime of cyclic administration includes administering the parathyroid hormone for at least about 12 to about 24 months and withdrawing parathyroid hormone for at least 6 months. Typically, the benefits of administration of a parathyroid hormone persist after a period of administration. The benefits of several months of administration can persist for as much as a year or two, or more, without additional administration.

For hPTH(1-34) in particular, in studies by the present applicant the lowest tested dose found to be biologically in human subjects, as indicated by detectable changes in various biochemical bone markers, was about 15µg; 6µg was found to produce no significant effects. Therefore, for reducing risk on cancer in men or women with hPTH(1-34) according to the present invention, preferably one should use a daily dose greater than about 6µg, more preferably at least about 15µg. Daily doses of hPTH(1-34) of 20µg and 40µg were both found to be similarly effective against osteoporosis in both men and women and both also have been shown to reduce the risk of cancer in human subjects as shown, for instance, in Example 1,

below. Higher daily doses of hPTH(1-34) have been used in human subjects previously, although it is believed that parathyroid hormone has never been shown to reduce the risk of cancer in human subjects. Therefore, any daily dose of hPTH(1-34) in the range of greater than about 6 μ g to at least about 40 μ g would be effective for reduction of the risk of cancer, according to the present method of using this form of parathyroid hormone. However, this applicant has found that a daily dose of about 20 μ g produced fewer undesirable side effects in human subjects than a daily dose of about 40 μ g. Hence, daily doses above about 40 μ g are less preferred than doses of 40 μ g or less; and a daily dose of about 20 μ g is more preferred than any higher dose from this perspective. Accordingly, the present invention provides a method for reducing the risk of cancer in a human subject at risk thereof, comprising administering to the subject a parathyroid hormone. Preferably, the parathyroid hormone consists of amino acid sequence 1-34 of human parathyroid hormone. This hormone may be administered with or without concurrent administration of an antiresorptive agent other than vitamin D or calcium. Preferably, the hormone is administered in a daily dose in the range of about 15 μ g to about 40 μ g, for at least about 12 months. In this method for reducing the risk of cancer, the hormone may be administered for longer periods of several years (e.g., up to 3 years as in osteoporotic patients), including for the remaining life of a human subject identified as having a high risk of cancer.

Uses of Formulations of a Parathyroid Hormone

The present invention also encompasses a kit including the present pharmaceutical compositions and to be used with the methods of the present invention. The kit can contain a vial or other container, such as a pen-style injection device or a cartridge for such a device, which contains a formulation of the present invention and suitable carriers, either dried or in liquid form. The kit further includes instructions in the form of a label on the vial and/or in the form of an insert included in a box in which the vial or other container is packaged, for the use and administration of the compounds. The instructions can also be printed on the box in which the vial or container is packaged. The instructions contain information such as sufficient dosage and administration information so as to allow a worker in the field to administer the

drug. It is anticipated that a worker in the field encompasses any doctor, nurse, or technician who might administer the drug or oversee self-administration of the drug by a human subject.

The present invention also relates to a pharmaceutical composition including
5 a formulation of one or more parathyroid hormones, such as human PTH(1-84) or human PTH(1-34), and that is suitable for parenteral administration. According to the invention, a formulation of one or more parathyroid hormones, such as human PTH(1-84) or human PTH(1-34), can be used for manufacturing a composition or medicament suitable for administration by parenteral administration. The invention
10 also relates to methods for manufacturing compositions including a formulation of one or more parathyroid hormones, such as human PTH(1-84) or human PTH(1-34), in a form that is suitable for parenteral administration. For example, a liquid or solid formulation can be manufactured in several ways, using conventional techniques. A liquid formulation can be manufactured by dissolving the one or parathyroid
15 hormones, such as human PTH(1-84) or human PTH(1-34), in a suitable solvent, such as water, at an appropriate pH, including buffers or other excipients, for example to form one of the stabilized solutions described hereinabove.

The example which follows is illustrative of the invention and is not intended
20 to be limiting.

EXAMPLE**Example 1 - - Reduced Risk of Cancer****Upon Administration of rhPTH(1-34) to Humans**

Number of Subjects: rhPTH(1-34): 1093 enrolled, 848 finished.
 Placebo: 544 enrolled, 447 finished.

Diagnosis and Inclusion Criteria: Women ages 30 to 85 years, postmenopausal for a minimum of 5 years, with a minimum of one moderate or two mild atraumatic vertebral fractures.

Dosage and Administration: Test Product (blinded)
 rhPTH(1-34): 20 µg/day, given subcutaneously
 rhPTH(1-34): 40 µg/day, given subcutaneously
Reference Therapy (blinded)
 Placebo study material for injection

Duration of Treatment: rhPTH(1-34): 17-23 months (excluding 6-month run-in phase)
 Placebo: 17-23 months (excluding 6-month run-in phase)

Criteria for Evaluation: Spine x-ray; serum biological markers (calcium, bone-specific alkaline phosphatase, procollagen I carboxy-terminal propeptide); urine markers (calcium, N-telopeptide, free deoxypyridinoline); 1,25-dihydroxyvitamin D; bone mineral density: spine, hip, wrist, and total body; height; population pharmacokinetics; bone biopsy (selected study sites).

Patient Characteristics

	Placebo (N=544)	PTH-20 (N=541)	PTH-40 (N=552)	p-value
Caucasian	98.9%	98.9%	98.4%	0.672
Age	69.0±7.0	69.5±7.1	69.9±6.8	0.099
Years post menopausal	20.9±8.5	21.5±8.7	21.8±8.2	0.273
Hysterectomized	23.8%	23.1%	21.6%	0.682
Uterus + 0 or 1 ovary	57	51	58	
Uterus + 2 ovaries	61	57	51	
Unknown	11	17	10	
Previous osteoporosis drug use	14.9%	15.5%	13.0%	0.479
Baseline spine BMD	0.82±0.17	0.82±0.17	0.82±0.17	>0.990
Baseline # of vert. fx				>0.990
0	54 (10.4%)	45 (8.8%)	54 (10.1%)	
1	144 (27.8%)	159 (31.1%)	169 (31.6%)	
2	128 (24.7%)	128 (25.0%)	125 (23.4%)	
3	75 (14.5%)	67 (13.1%)	81 (15.1%)	
4	59 (11.4%)	49 (9.6%)	45 (8.4%)	
5	28 (5.4%)	31 (6.1%)	21 (3.9%)	
6	13 (2.5%)	20 (3.9%)	25 (4.7%)	
7	6 (1.2%)	7 (1.4%)	10 (1.9%)	
8	9 (1.7%)	5 (1.0%)	3 (0.6%)	
9	1 (0.2%)	0	2 (0.4%)	
10	1 (0.2%)	1 (0.2%)	0	
Unspecified	26	29	17	

Results

- 5 Table 1 illustrates data showing the reduction in the number of patients having detectable tumors upon treatment with PTH.

Table 1. Effect of PTH on the incidence of cancer expressed as number (and percentage) of patients with detectable tumors

	Placebo (N=544)	PTH-20 (N=541)	PTH-40 (N=522)	p-value
Breast carcinoma	7 (1.29%)	1 (0.185%)	1 (0.192%)	0.017
Skin carcinoma	5 (0.919%)	2 (0.370%)	4 (0.766%)	0.532
All cancers	21 (3.86%)	8 (1.48%)	11 (2.11%)	0.03
All cancers except breast carcinoma	16 (2.94%)	7 (1.30%)	10 (1.92%)	

10

The percentage of patients with any form of detectable cancer was significantly lower in PTH-treated patients than in placebo-treated patients (1.79%

vs. 3.86%, respectively, $p=0.03$) when all PTH-treated patients were compared to the placebo control group. The percentage of PTH patients with detectable cancer at 20 $\mu\text{g/day}$ was 1.48% and at 40 $\mu\text{g/day}$ was 2.11% (Table 1).

Similarly, the percentage of patients with breast carcinoma was significantly
5 lower in PTH-treated patients than in placebo-treated patients (0.188% vs. 1.29%, respectively, $p=0.017$) when all PTH-treated patients were compared to the placebo-treated group. The percentage of PTH patients with detectable breast carcinoma at 20 $\mu\text{g/day}$ was 0.185% and at 40 $\mu\text{g/day}$ was 0.195% (Table 1). Although subjects included in this study had 1 or more fractures, many had bone
10 mass within an age-matched normal range. Thus, subjects in this clinical trial might be expected to show a comparable incidence of breast cancer to that of the general population.

The percentage of patients with skin carcinoma was also lower in PTH-treated patients than in placebo-treated patients (0.564% vs. 0.919%, respectively,
15 $p=0.532$). The percentage of PTH patients with detectable skin carcinoma at 20 $\mu\text{g/day}$ was 0.370% and at 40 $\mu\text{g/day}$ was 0.766% (Table 1).

Additionally, the percentage of patients with any form of detectable cancer, excluding breast carcinoma, was lower in PTH-treated patients than in placebo-treated patients (1.60% vs. 2.94%, respectively) when all PTH-treated patients were
20 compared to placebo. The percentage of PTH patients with detectable cancer, excluding breast carcinoma, at 20 $\mu\text{g/day}$ was 1.30% and at 40 $\mu\text{g/day}$ was 1.92% (Table 1).

In summary, the data presented above indicate that patients treated with PTH have a reduced risk of cancer. Particularly, the incidence of breast cancer was
25 significantly lower in the PTH-treated patient population relative to placebo controls. Furthermore, the total incidence of any form of cancer was significantly lower in PTH-treated patients relative to placebo controls. This decrease in the incidence of cancer in PTH-treated patients is not entirely due to the reduction in the incidence of breast carcinoma, as the trend towards lower incidence of cancer
30 remains when breast cancer is excluded. Therefore, administration of PTH decreases the risk of cancer.

Discussion

These data on cancer are the first data on the reduction of cancer risk by PTH in humans. These findings demonstrate a significantly lower incidence of overall
5 cancer. In addition, certain cancers, skin carcinoma and breast carcinoma, were reduced in patients administered PTH. Of particular interest is the lower incidence of breast cancer observed in patients treated with PTH relative to placebo controls. Investigation of the records of affected patients indicated that this reduction in incidence of new breast cancer cases was a treatment-dependent phenomenon.

10

* * *

The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention. All publications and patent applications in this specification
15 are indicative of the level of ordinary skill in the art to which this invention pertains.

WE CLAIM:

1. A method for reducing risk of cancer in a human subject in need thereof, comprising administering to the subject an effective amount of a parathyroid hormone.
5
2. The method of claim 1, wherein the cancer comprises a carcinoma.
3. The method of claim 2, wherein the cancer comprises breast carcinoma, skin carcinoma, bladder carcinoma, gastric carcinoma, or a combination thereof.
10
4. The method of claim 1, wherein the cancer comprises breast carcinoma.
15
5. The method of claim 4, wherein the breast carcinoma comprises estrogen dependent carcinoma.
6. The method of claim 4, wherein the breast carcinoma comprises estrogen independent carcinoma.
20
7. The method of claim 1, wherein the subject is a woman identified as having a relatively high risk of breast cancer.
- 25 8. The method of claim 7 wherein said high risk of breast cancer is based on age at menarche, age at first live birth, number of previous biopsies, and number of first-degree relatives with breast cancer.
9. The method of claim 7 wherein said high risk of breast cancer is
30 based a relatively high level of bioavailable serum estradiol or of free testosterone.

10. The method of claim 1, wherein the subject is a woman identified as having a high risk of or as suffering from osteoporosis.

11. The method of claim 10, wherein the subject is a postmenopausal
5 woman.

12. The method of claim 11, wherein the woman is not concurrently taking hormone replacement therapy or an antiresorptive.

10 13. The method of claim 10, wherein the subject is a woman in an early stage of osteoporosis or in an advanced stage of osteoporosis.

14. The method of claim 1, wherein the parathyroid hormone comprises a fragment of a parathyroid hormone selected from the group consisting of PTH(1-
15 31), PTH(1-34), PTH(1-37), PTH(1-38), and PTH(1-41).

15. The method of claim 1, wherein the parathyroid hormone is human PTH(1-34).

20 16. The method of claim 1, wherein the parathyroid hormone is human PTH(1-84).

17. The method of claim 1, comprising administering to said subject a parathyroid hormone consisting of amino acid sequence 1-34 of human parathyroid
25 hormone in a daily dose of in a daily dose of at least about 15 µg to about 40 µg for at least about 12 months.

18. The method of claim 1, further comprising administering calcium, vitamin D, or a combination thereof.

30

19. The method of claim 1, wherein reducing the risk of cancer further comprises reducing, ameliorating, or repairing cancer induced bone damage.

20. A process for manufacturing a medicament used for reducing risk of cancer, comprising combining a parathyroid hormone with a pharmaceutically acceptable carrier.

5

21. The process of claim 20, wherein the medicament comprises a stabilized formulation of a parathyroid hormone.

22. The process of claim 21, wherein the stabilized formulation
10 comprises:

a therapeutically effective amount of a parathyroid hormone;

a polyol, such as mannitol or propylene glycol;

a buffering agent suitable for maintaining the pH of the composition within a range of about 3-7, such as an acetate or tartrate source; and

15

water.

23. Use of a parathyroid hormone for the manufacture of a medicament for reducing the risk of cancer in a subject in need thereof.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/24746

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/29 A61P35/04 A61P19/08 //(A61K38/29,31:59),
(A61K38/29,30:06),(A61K38/29,31:59,30:06)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ, MEDLINE, CHEM ABS Data, EMBASE, SCISEARCH, CANCERLIT

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 840 690 A (HOLICK MICHAEL F) 24 November 1998 (1998-11-24) column 3, line 64 -column 4, line 14 claims 1-11 ---	1,14,15, 17,20-23
A	EP 0 878 201 A (CHUGAI PHARMACEUTICAL CO LTD) 18 November 1998 (1998-11-18) the whole document ---	1-23
A	WO 96 03437 A (SANDOZ AG ;GAMSE RAINER (CH); SANDOZ LTD (CH); CARDINAUX FRANCOIS) 8 February 1996 (1996-02-08) page 15, line 30 -page 16, line 2 ---	1-23
A	EP 0 197 514 A (GEN HOSPITAL CORP) 15 October 1986 (1986-10-15) the whole document ---	1-23
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

20 February 2001

Date of mailing of the international search report

01/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Stein, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/24746

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>TREMBLING P ET AL: "Comparison of effects of PTHrP 1-34, PTHrP 1-86 and PTH on proliferation of breast cancer cells." JOURNAL OF ENDOCRINOLOGY, vol. 144, no. SUPPL., 1995, page P223 XP000982364 ISSN: 0022-0795 the whole document</p>	1-23
A	<p>DELMAS P D ET AL: "Bone loss induced by cancer treatment and its management." EUROPEAN JOURNAL OF CANCER, vol. 34, no. 2, February 1998 (1998-02), pages 260-262, XP000982362 ISSN: 0959-8049 the whole document</p>	10,13,19
A	<p>AIGINGER P ET AL: "THERAPY OF MULTIPLE BONE METASTASES WITH PARATHYROID HORMONE AND RADIO PHOSPHORUS" OESTERREICHISCHE ZEITSCHRIFT FUER ONKOLOGIE, vol. 2, no. 1, 1975, pages 17-24, XP000982314 ISSN: 0377-2004 the whole document</p>	1,16-23

INTERNATIONAL SEARCH REPORT

Information on patent family members

Interna. Application No

PCT/US 00/24746

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5840690	A	24-11-1998	US 5527772 A	18-06-1996
			US 6066618 A	23-05-2000
			WO 9204039 A	19-03-1992
			AT 138685 T	15-06-1996
			AU 2788089 A	23-05-1989
			CA 1326460 A	25-01-1994
			DE 3855331 D	04-07-1996
			DE 3855331 T	24-10-1996
			EP 0415924 A	13-03-1991
			JP 2802084 B	21-09-1998
			JP 3505517 T	05-12-1991
			WO 8903873 A	05-05-1989
EP 0878201	A	18-11-1998	AU 1558197 A	22-08-1997
			JP 9301887 A	25-11-1997
			WO 9727870 A	07-08-1997
WO 9603437	A	08-02-1996	AU 3167095 A	22-02-1996
			BR 9508433 A	14-07-1998
			CA 2192787 A	08-02-1996
			CZ 9700233 A	16-07-1997
			EP 0773958 A	21-05-1997
			FI 970168 A	15-01-1997
			HU 77979 A	28-01-1999
			JP 10502091 T	24-02-1998
			NO 970356 A	28-01-1997
			PL 318017 A	12-05-1997
			SK 12097 A	06-08-1997
			TR 960095 A	21-06-1996
			ZA 9506331 A	28-01-1997
EP 0197514	A	15-10-1986	AT 79271 T	15-08-1992
			AU 599905 B	02-08-1990
			AU 5561686 A	09-10-1986
			CA 1288695 A	10-09-1991
			DE 3686343 A	17-09-1992
			DE 3686343 T	28-01-1993
			DK 155686 A	05-10-1986
			IE 59620 B	09-03-1994
			IL 78342 A	10-06-1991
			JP 7072138 B	02-08-1995
			JP 62000033 A	06-01-1987
			JP 2531505 B	04-09-1996
			JP 7179358 A	18-07-1995
			PH 23720 A	03-11-1989
			US 4698328 A	06-10-1987
			ZA 8602510 A	26-11-1986